primaquine has been researched along with Leishmaniasis, Visceral in 9 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Excerpt | Relevance | Reference |
|---|---|---|
| "8-Aminoquinolines are an important class of antiparasitic agents, with broad utility and excellent efficacy, but also limitations due to hematological toxicities, primarily methemoglobinemia and hemolysis." | 3.74 | Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. ( Ager, AL; Bartlett, MS; Croft, SL; Khan, IA; McChesney, JD; Nanayakkara, NP; Walker, LA; Yardley, V, 2008) |
| " However, primaquine exhibits low oral bioavailability due to oxidative deamination of its aliphatic chain." | 1.38 | Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum. ( Gomes, MS; Gomes, P; Matos, J; Moreira, R; Tomás, A; Vale, N; Vale-Costa, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shetty, RV | 1 |
| Blanton, CD | 1 |
| Nanayakkara, NP | 1 |
| Ager, AL | 1 |
| Bartlett, MS | 1 |
| Yardley, V | 1 |
| Croft, SL | 2 |
| Khan, IA | 1 |
| McChesney, JD | 1 |
| Walker, LA | 1 |
| Castanys-Muñoz, E | 1 |
| Pérez-Victoria, JM | 1 |
| Gamarro, F | 1 |
| Castanys, S | 1 |
| Vale-Costa, S | 1 |
| Vale, N | 1 |
| Matos, J | 1 |
| Tomás, A | 1 |
| Moreira, R | 1 |
| Gomes, P | 1 |
| Gomes, MS | 1 |
| Steck, EA | 1 |
| Burghard, H | 1 |
| DeWitt Blanton, C | 1 |
| Rodrigues, JM | 1 |
| Fessi, H | 1 |
| Bories, C | 1 |
| Devissaguet, JP | 1 |
| Gaspar, R | 1 |
| Opperdoes, FR | 1 |
| Préat, V | 1 |
| Roland, M | 1 |
| Zhong, HL | 1 |
| Zhang, NZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for primaquine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
The chemotherapy of protozoal infections: whither?
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Models, Animal; Glycolip | 1981 |
Studies on leishmaniasis in China. Historical background, epidemiology, clinical aspects, legislature and control program.
Topics: Animals; China; Humans; Legislation, Medical; Leishmaniasis, Visceral; Liposomes; Primaquine | 1986 |
7 other studies available for primaquine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Synthesis of 2-substituted primaquine analogues as potential antimalarials.
Topics: Animals; Antimalarials; Cricetinae; Haplorhini; Leishmaniasis, Visceral; Macaca mulatta; Malaria; Mi | 1978 |
Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.
Topics: Aminoquinolines; Animals; Antifungal Agents; Antiprotozoal Agents; Dogs; Female; Hemolysis; Humans; | 2008 |
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Base Sequence; Bi | 2008 |
Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Cell Culture Techniques; Cell Survival; Inhibitory C | 2012 |
4,5-disubstituted primaquine analogs as potential antiprotozoan agents.
Topics: Animals; Antiprotozoal Agents; Chemical Phenomena; Chemistry; Cricetinae; Haplorhini; Leishmaniasis, | 1980 |
The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice.
Topics: Animals; Delayed-Action Preparations; Drug Carriers; Female; In Vitro Techniques; Leishmania donovan | 1994 |
Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani.
Topics: Animals; Cell Line; Cyanoacrylates; Dose-Response Relationship, Drug; Drug Carriers; In Vitro Techni | 1992 |